Frequency and safety of pegfilgrastim use in patients with lung cancer treated with combination therapy of cytotoxic chemotherapy and immune checkpoint inhibitors: A CS-lung-003-registry-based prospective observational study
Frequency and safety of pegfilgrastim use in patients with lung cancer treated with combination therapy of cytotoxic chemotherapy and immune checkpoint inhibitors: A CS-lung-003-registry-based prospective observational study. // JAAD International. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000653?dgcid=rss_sd_all
Frequency and safety of pegfilgrastim use in patients with lung cancer treated with combination therapy of cytotoxic chemotherapy and immune checkpoint inhibitors: A CS-lung-003-registry-based prospective observational study. JAAD International. https://www.sciencedirect.com/science/article/pii/S3117504X26000653?dgcid=rss_sd_all
“Frequency and safety of pegfilgrastim use in patients with lung cancer treated with combination therapy of cytotoxic chemotherapy and immune checkpoint inhibitors: A CS-lung-003-registry-based prospective observational study.” JAAD International.
@article{article5798,
title = {Frequency and safety of pegfilgrastim use in patients with lung cancer treated with combination therapy of cytotoxic chemotherapy and immune checkpoint inhibitors: A CS-lung-003-registry-based prospective observational study},
journal = {JAAD International},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000653?dgcid=rss_sd_all}
}